Prof. Basile Njei

28/09/2025

Our latest article published in BMC Gastroenterology:
“Cancer disparities in lean vs. non-lean MASH: insight from a national inpatient sample.”

📌 Key Findings:
🔹 Lean MASH (metabolic dysfunction-associated steatohepatitis) patients face higher odds of several cancers including lung, colon, kidney, liver, cervical cancers, and non-Hodgkin’s lymphoma despite having a lower BMI.
🔹 Non-lean MASH patients, by contrast, demonstrated higher odds of endometrial cancer.
🔹 This underscores that BMI alone does not fully capture cancer risk in MASH populations.

Grateful to my co-authors Chukwunonso Ezeani, Chidiebele Omaliko, Petr Protiva, Yazan Al-Ajlouni, and Gyanprakash Ketwaroo for their collaboration on this important work.

Lean MASH hospitalizations are linked to higher odds of several cancers despite lower BMI, underscoring the need for a nuanced understanding of cancer risks in MASH. BMI alone may not fully capture oncologic risk in this population.

27/09/2025

Using the heart to predict liver disease 🔥

29/08/2025

A Cameroonian doctor is proving that skinny people can have deadly liver disease too Doctors have been getting it wrong for years. They thought if you're skinny with a normal weight, your liver is fine. But Dr. Basile Njei, a liver doctor from Cameroon who now works at Yale University, has discovere...

13/08/2025

29/07/2025

📢 New in Dig Dis Sci:
Outcomes of Acute Pancreatitis in Lean vs Non-lean MASLD
🔍 NIS 2016–2020
➡️ Non-lean MASLD = ↑ costs, LOS, sepsis, ERCP
➡️ Mortality = similar
👨‍⚕️ Lean MASLD needs tailored strategies

By Addo Ameyaw et al. ft.

Our study suggests that lean MASLD patients with AP may experience a higher rate of hospital admissions and distinct clinical profiles, including a similar mortality risk compared to non-lean MASLD patients, indicating a complex relationship between AP outcomes and MASLD beyond BMI.

18/07/2025

📢 New Study Published in Clinical Research in Hepatology and Gastroenterology 📢

Excited to share our latest nationwide analysis:
“Trends, disparities, and outcomes of drug-induced pancreatitis in the United States (2016–2020)”
👉 Read on PubMed

🩺 Why this matters:
Drug-induced pancreatitis (DIP) remains underrecognized despite growing prevalence due to rising polypharmacy. Using data from over 5,600 hospitalized patients across the U.S., we highlight significant racial disparities, clinical complications, and economic burden associated with DIP.

🔍 Key Findings:
• Higher odds of severe disease in Black patients
• Increased risk of cardiac arrest in Hispanic patients
• Asian patients faced longer hospital stays, greater costs, and increased risk of sepsis
• Average hospital charges: $60K+
• Mean hospital stay: 5.5 days
• Most common complications: acute kidney injury (20.6%), sepsis, ileus

⚠️ The study underscores the urgent need for targeted prevention, early identification, and equity-focused care strategies to mitigate the impact of DIP.

📚 Grateful to collaborate with a brilliant team:
Guy Loic Nguefang Tchoukeu, Sarpong Boateng, Joel Gabin Konlack Mekontso, Yazan Al-Ajlouni, and myself.

There are significant racial disparities among patients and a substantial economic burden on healthcare systems. Multifaceted strategies and research into genetic and socioeconomic predispositions are needed to address DIP.

01/07/2025

https://m.euclid.int/euclid-university-welcomes-professor-basile-njei-md-mph-phd-to-its-distinguished-faculty/

EUCLID University, a global leader in intergovernmental higher education, is thrilled to announce the appointment of Professor Basile Njei, MD, MPH, PhD, as a distinguished consulting faculty member in its School of Global Health and Bioethics. A world-renowned expert in digestive diseases and a tra...

09/06/2025

Honored to receive these recognitions during my academic visit to Jordan. Grateful to Prof. Dr. Ahmad Al-Ajlouni & Al-Balqa Applied University for the warm welcome. Excited to build on our shared vision in AI, global health & education.